PortfoliosLab logo
Novartis AG (0QLR.L)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

CH0012005267

Highlights

Market Cap

£195.43B

Year Range

£81.22 - £115.94

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Novartis AG (0QLR.L) returned 2.20% year-to-date (YTD) and -2.09% over the past 12 months.


0QLR.L

YTD

2.20%

1M

4.97%

6M

-2.01%

1Y

-2.09%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.08%

1M

9.75%

6M

-1.63%

1Y

12.74%

5Y*

15.66%

10Y*

10.77%

*Annualized

Monthly Returns

The table below presents the monthly returns of 0QLR.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20259.07%0.94%0.52%-4.20%-3.62%2.20%
20246.50%-0.38%-2.87%2.49%4.63%3.07%2.53%3.68%-4.68%-3.43%-0.85%-4.94%5.03%
2023-2.01%-3.10%4.67%8.73%-4.26%3.23%1.20%-1.94%5.38%-5.16%0.35%-0.63%5.62%
2022-1.22%1.34%1.30%6.07%0.38%-6.57%2.16%-4.52%-4.55%7.21%3.30%0.77%4.81%
20214.41%-3.00%1.60%5.96%-0.98%1.53%-9.37%-1.56%-3.07%9.74%4.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 0QLR.L is 49, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of 0QLR.L is 4949
Overall Rank
The Sharpe Ratio Rank of 0QLR.L is 4545
Sharpe Ratio Rank
The Sortino Ratio Rank of 0QLR.L is 4444
Sortino Ratio Rank
The Omega Ratio Rank of 0QLR.L is 4444
Omega Ratio Rank
The Calmar Ratio Rank of 0QLR.L is 5656
Calmar Ratio Rank
The Martin Ratio Rank of 0QLR.L is 5555
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Novartis AG (0QLR.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Novartis AG Sharpe ratios as of May 14, 2025 (values are recalculated daily):

  • 1-Year: -0.10
  • All Time: 0.30

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Novartis AG compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History

Novartis AG provided a 0.00% dividend yield over the last twelve months, with an annual payout of £0.00 per share. The company has been increasing its dividends for 10 consecutive years.


0.00%£0.00£0.00£0.00£0.00£0.00£0.00£0.0020142015201620172018201920202021202220232024
Dividends
Dividend Yield
PeriodTTM20242023202220212020201920182017201620152014
Dividend£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00

Dividend yield

0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Monthly Dividends

The table displays the monthly dividend distributions for Novartis AG. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025£0.00£0.00£0.00£0.00£0.00£0.00
2024£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00
2023£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00
2022£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00
2021£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00£0.00
2020£0.00£0.00
2019£0.00£0.00
2018£0.00£0.00
2017£0.00£0.00
2016£0.00£0.00
2015£0.00£0.00
2014£0.00£0.00

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Novartis AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Novartis AG was 18.01%, occurring on Apr 9, 2025. The portfolio has not yet recovered.

The current Novartis AG drawdown is 11.34%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-18.01%Sep 3, 2024151Apr 9, 2025
-15.8%May 27, 202281Sep 26, 2022140Apr 17, 2023221
-15.47%Aug 18, 202174Nov 30, 202189Apr 8, 2022163
-10.2%Jan 23, 202461Apr 18, 202430Jun 5, 202491
-8.96%May 10, 202348Jul 17, 202351Sep 28, 202399

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Novartis AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Novartis AG, comparing actual results with analytics estimates.


1.002.003.004.005.006.007.0020212022202320242025
1.64
Actual
Estimate

Valuation

The Valuation section provides an overview of how Novartis AG is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for 0QLR.L relative to other companies in the Drug Manufacturers - General industry. Currently, 0QLR.L has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for 0QLR.L in comparison with other companies in the Drug Manufacturers - General industry. Currently, 0QLR.L has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items